<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2023-8.5.8</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4440</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group></article-categories><title-group><article-title>Диффузная крупноклеточная B-клеточная лимфома яичка. Клиническая лекция и наблюдение из практики</article-title><trans-title-group xml:lang="en"><trans-title>Testicular diffuse large B-cell lymphoma. Clinical lecture and case report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9278-9739</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лелявин</surname><given-names>К. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lelyavin</surname><given-names>K. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лелявин Кирилл Борисович – доктор медицинских наук, доцент кафедры скорой медицинской помощи и медицины катастроф </p><p>664049, г. Иркутск, Юбилейный, 100</p></bio><bio xml:lang="en"><p>Kirill B. Lelyavin – Dr. Sc. (Med.), Associate Professor at the Department of Emergency Medical Services and Disaster Medicine </p><p>Yubileyniy 100, Irkutsk 664049</p></bio><email xlink:type="simple">LelyavinK@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6248-5774</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тараненко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Taranenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тараненко Андрей Валентинович – кандидат медицинских наук, ассистент кафедры онкологии </p><p>664049, г. Иркутск, Юбилейный, 100</p></bio><bio xml:lang="en"><p>Andrey V. Taranenko – Cand. Sc. (Med.), Teaching Assistant at the Department of Oncology </p><p>Yubileyniy 100, Irkutsk 664049</p></bio><email xlink:type="simple">docandrtar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-2045-3206</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брюханов</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bryukhanov</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Брюханов Владимир Геннадьевич – врач лучевой диагностики </p><p>664007, г. Иркутск, ул. Карла Либкнехта, 9</p></bio><bio xml:lang="en"><p>Vladimir G. Bryukhanov– Radiologist </p><p>Karla Liebknekhta str. 9, Irkutsk 664007</p></bio><email xlink:type="simple">vbr72@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Иркутская государственная медицинская академия последипломного образования – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff><aff xml:lang="en"><institution>Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Центр магнитно-резонансной томографии «МРТ-Лидер»</institution></aff><aff xml:lang="en"><institution>Center for Magnetic Resonance Imaging “MRT-Lider”</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><volume>8</volume><issue>5</issue><fpage>81</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лелявин К.Б., Тараненко А.В., Брюханов В.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Лелявин К.Б., Тараненко А.В., Брюханов В.Г.</copyright-holder><copyright-holder xml:lang="en">Lelyavin K.B., Taranenko A.V., Bryukhanov V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4440">https://www.actabiomedica.ru/jour/article/view/4440</self-uri><abstract><p>Лимфома представляет собой гетерогенную группу злокачественных новообразований лимфоцитов, которые могут вовлекать лимфатическую ткань, костный мозг или экстранодальные локализации. В лекции приводится краткий обзор современного состояния проблемы диагностики и лечения первичной лимфомы яичка. Первичная лимфома яичка (ПЛЯ) является редкой лимфоидной злокачественной опухолью. ПЛЯ, хотя и встречается редко, представляет собой наиболее распространённый вид опухоли яичка у  мужчин старше 60  лет. Наиболее часто встречающимся гистологическим типом является диффузная крупноклеточная В-клеточная лимфома. На  сегодняшний день нет хорошо задокументированных этиологических факторов или факторов риска ПЛЯ. В отличие от других распространённых новообразований яичка, не наблюдалось статистически значимой связи ПЛЯ с крипторхизмом, травмой, хроническим орхитом или бесплодием. Ультразвуковое исследование, как правило, является методом визуализации первой линии, используемым для характеристики поражений яичка. ПЛЯ проявляется в виде гипоэхогенного образования, которое может иметь вид  как одиночного крупного образования, так и множественных мелких образований, занимающих большую часть паренхимы яичка или полностью её замещающих. Системное лечение, включая орхиэктомию, химиотерапию, лучевую терапию и интратекальную профилактику, необходимо для всех пациентов с ПЛЯ. Помимо достижения полной ремиссии, целью лечения ПЛЯ является предотвращение рецидивов в контралатеральное яичко и  центральную нервную систему. Представленный материал дополнен собственным наблюдением и иллюстративным материалом. Персональные медицинские данные публикуются с письменного согласия пациента. В нашем случае возраст пациента составил 38 лет, что не попадает в указанную возрастную группу для первичной лимфомы яичка. На наш взгляд, публикация данного клинического случая и анализа научной литературы по данной теме является актуальной.</p></abstract><trans-abstract xml:lang="en"><p>Lymphoma is a heterogeneous group of lymphocyte malignancies that may involve lymphatic tissue, bone marrow, or extranodal sites. The lecture provides a  brief overview of the current state of the problem of diagnosis and treatment of primary testicular lymphoma. Primary testicular lymphoma (PTL) is a rare lymphoid malignancy. Though it is rare, PTL is the most common type of testicular tumor in men over 60 years of age. The most common histological type is diffuse large B-cell lymphoma. To date, there are no well-documented etiological or risk factors for PTL. In contrast to other common testicular neoplasms, there was no statistically significant association of PTL with cryptorchidism, trauma, chronic orchitis, or infertility. Ultrasound is generally the first-line imaging method used to characterize testicular lesions. PTL manifests itself in the form of a hypoechoic formation, which can take the form of either a single large formation or multiple small formations that occupy most of the testicular parenchyma or completely replace it. Systemic treatment, including orchiectomy, chemotherapy, radiation therapy, and intrathecal prophylaxis, is necessary for all patients with PTL. In addition to achieving complete remission, the goal of PTL treatment is to prevent recurrences in the contralateral testis and central nervous system. The presented information is supplemented by our own observation and images. Personal medical data is published with the written consent of the patient. In our case, the patient’s age was 38 years, which does not fall into the specified age group for primary testicular lymphoma. In our opinion, the publication of this clinical case and analysis of scientific literature on this topic are relevant.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диффузная крупноклеточная В-клеточная лимфома</kwd><kwd>первичная лимфома яичка</kwd><kwd>неходжкинская лимфома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diffuse large B-cell lymphoma</kwd><kwd>primary testicular lymphoma</kwd><kwd>nonHodgkin lymphoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Menter T, Ernst M, Drachneris J, Dirnhofer S, Barghorn A, Went P, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014; 32: 72-81. doi: 10.1002/hon.2090</mixed-citation><mixed-citation xml:lang="en">Menter T, Ernst M, Drachneris J, Dirnhofer S, Barghorn A, Went P, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014; 32: 72-81. doi: 10.1002/hon.2090</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Казакевич В.И., Митина Л.А., Скрепцова Н.С., Востров А.Н., Майорова М.В., Прозорова Э.В., и др. Ультразвуковое исследование при лимфоме с поражением малого таза. Ультразвуковая и функциональная диагностика. 2015; 4S: 75-76.</mixed-citation><mixed-citation xml:lang="en">Kazakevich VI, Mitina LA, Skreptsova NS, Vostrov AN, Mayorova MV, Prozorova EV, et al. Ultrasound examination in lymphoma with pelvic involvement. Ultrasound and Functional Diagnostics. 2015; 4S: 75-76. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Curling TB. A practical treatise on the diseases of testis and of the spermatic cord and scrotum. Philadelphia; 1856.</mixed-citation><mixed-citation xml:lang="en">Curling TB. A practical treatise on the diseases of testis and of the spermatic cord and scrotum. Philadelphia; 1856.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Malassez M. Lymphadenome du testicule, rapport sur la candidature de M. Letulle, interne des hospitaux au titre de member adjoint. Bull Soc Anta (Paris). 1877; 52: 176-178.</mixed-citation><mixed-citation xml:lang="en">Malassez M. Lymphadenome du testicule, rapport sur la candidature de M. Letulle, interne des hospitaux au titre de member adjoint. Bull Soc Anta (Paris). 1877; 52: 176-178.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). 2021; 9(1): 5. doi: 10.3390/medsci9010005</mixed-citation><mixed-citation xml:lang="en">Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). 2021; 9(1): 5. doi: 10.3390/medsci9010005</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and treatment. Am Fam Physician. 2020; 101(1): 34-41.</mixed-citation><mixed-citation xml:lang="en">Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and treatment. Am Fam Physician. 2020; 101(1): 34-41.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569</mixed-citation><mixed-citation xml:lang="en">Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, et al. Primary lymphomas of the genitourinary tract: A population-based study. Asian J Urol. 2020; 7(4): 332-339. doi: 10.1016/j.ajur.2019.11.002</mixed-citation><mixed-citation xml:lang="en">Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, et al. Primary lymphomas of the genitourinary tract: A population-based study. Asian J Urol. 2020; 7(4): 332-339. doi: 10.1016/j.ajur.2019.11.002</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ma RZ, Tian L, Tao LY, He HY, Li M, Lu M, et al. The survival and prognostic factors of primary testicular lymphoma: Two-decade single-center experience. Asian J Androl. 2018; 20(6): 615-620. doi: 10.4103/aja.aja_73_18</mixed-citation><mixed-citation xml:lang="en">Ma RZ, Tian L, Tao LY, He HY, Li M, Lu M, et al. The survival and prognostic factors of primary testicular lymphoma: Two-decade single-center experience. Asian J Androl. 2018; 20(6): 615-620. doi: 10.4103/aja.aja_73_18</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999; 26: 259-269.</mixed-citation><mixed-citation xml:lang="en">Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999; 26: 259-269.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Тумян Г.С., Ковригина А.М., Тимофеева О.Л., Пробатова Н.А., Шолохова Е.Н., Тупицын Н.Н., и др. Особенности клинического течения и прогноз больных неходжкинской лимфомой с первичной локализацией в яичке. Современная онкология. 2006; 8(4): 22-26.</mixed-citation><mixed-citation xml:lang="en">Tumyan GS, Kovrigina AM, Timofeeva OL, Probatova NA, Sholokhova EN, Tupitsyn NN, et al. Features of the clinical course and prognosis of patients with non-Hodgkin lymphoma with primary localization in the testicle. Journal of Modern Oncology. 2006; 8(4): 22-26. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol (R Coll Radiol). 2012; 24(5): 358-365. doi: 10.1016/j.clon.2012.02.005</mixed-citation><mixed-citation xml:lang="en">Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol (R Coll Radiol). 2012; 24(5): 358-365. doi: 10.1016/j.clon.2012.02.005</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen B, Cao DH, Lai L, Guo JB, Chen ZY, Huang Y, et al. Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. BMC Cancer. 2020; 20(1): 220. doi: 10.1186/s12885-020-6711-0</mixed-citation><mixed-citation xml:lang="en">Chen B, Cao DH, Lai L, Guo JB, Chen ZY, Huang Y, et al. Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. BMC Cancer. 2020; 20(1): 220. doi: 10.1186/s12885-020-6711-0</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017; 38(8): 812-820. doi: 10.1093/carcin/bgx061</mixed-citation><mixed-citation xml:lang="en">Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017; 38(8): 812-820. doi: 10.1093/carcin/bgx061</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts WC, Glancy DL, Devita VT. Heart in malignant lymphoma (Hodgkin’s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides): A study of 196 autopsy cases. Am J Cardiol. 1968; 22: 85-107. doi: 10.1016/0002-9149(68)90250-6</mixed-citation><mixed-citation xml:lang="en">Roberts WC, Glancy DL, Devita VT. Heart in malignant lymphoma (Hodgkin’s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides): A study of 196 autopsy cases. Am J Cardiol. 1968; 22: 85-107. doi: 10.1016/0002-9149(68)90250-6</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yasen Z, Kazzazi F, Ioannides K, Velmurugan S, Zegocki K, Li C. A case at crossroads-urological presentation, cardiac complication and haematological diagnosis: Should imaging be pursued prior to orchidectomy at all costs? J Surg Case Rep. 2021; 2021(5): rjab177. doi: 10.1093/jscr/rjab177</mixed-citation><mixed-citation xml:lang="en">Yasen Z, Kazzazi F, Ioannides K, Velmurugan S, Zegocki K, Li C. A case at crossroads-urological presentation, cardiac complication and haematological diagnosis: Should imaging be pursued prior to orchidectomy at all costs? J Surg Case Rep. 2021; 2021(5): rjab177. doi: 10.1093/jscr/rjab177</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011; 135(10): 1363-1367. doi: 10.5858/arpa.2010-0158-RS</mixed-citation><mixed-citation xml:lang="en">Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011; 135(10): 1363-1367. doi: 10.5858/arpa.2010-0158-RS</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Scott DW, Gascoyne RD. The tumor microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8): 517-534. doi: 10.1038/nrc3774</mixed-citation><mixed-citation xml:lang="en">Scott DW, Gascoyne RD. The tumor microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8): 517-534. doi: 10.1038/nrc3774</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Moses K, Brandau S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016; 28: 187-196. doi: 10.1016/j.smim.2016.03.018</mixed-citation><mixed-citation xml:lang="en">Moses K, Brandau S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016; 28: 187-196. doi: 10.1016/j.smim.2016.03.018</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007; 18: 171-182. doi: 10.1016/j.cytogfr.2007.01.015</mixed-citation><mixed-citation xml:lang="en">Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007; 18: 171-182. doi: 10.1016/j.cytogfr.2007.01.015</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013; 35: 163-176. doi: 10.1007/s00281-012-0344-6</mixed-citation><mixed-citation xml:lang="en">Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013; 35: 163-176. doi: 10.1007/s00281-012-0344-6</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019; 104(2): 338-346. doi: 10.3324/haematol.2018.200105</mixed-citation><mixed-citation xml:lang="en">Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019; 104(2): 338-346. doi: 10.3324/haematol.2018.200105</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Pathol Int. 2015; 65(10): 528-535. doi: 10.1111/pin.12336</mixed-citation><mixed-citation xml:lang="en">Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Pathol Int. 2015; 65(10): 528-535. doi: 10.1111/pin.12336</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell ymphoma. N Engl J Med. 2018; 378(15): 1396-1407. doi: 10.1056/NEJMoa1801445</mixed-citation><mixed-citation xml:lang="en">Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell ymphoma. N Engl J Med. 2018; 378(15): 1396-1407. doi: 10.1056/NEJMoa1801445</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(5): 604-616. doi: 10.1002/ajh.25460</mixed-citation><mixed-citation xml:lang="en">Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(5): 604-616. doi: 10.1002/ajh.25460</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzu D, Jeffrey RB Jr, Ralls PW. Lymphoma and leukemia involving the testicles: Findings on gray-scale and color Doppler sonography. AJR Am J Roentgenol. 1995; 164: 645-647. doi: 10.2214/ajr.164.3.7863887</mixed-citation><mixed-citation xml:lang="en">Mazzu D, Jeffrey RB Jr, Ralls PW. Lymphoma and leukemia involving the testicles: Findings on gray-scale and color Doppler sonography. AJR Am J Roentgenol. 1995; 164: 645-647. doi: 10.2214/ajr.164.3.7863887</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012; 120: 3222-3228. doi: 10.1182/blood-2012-04-423095</mixed-citation><mixed-citation xml:lang="en">Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012; 120: 3222-3228. doi: 10.1182/blood-2012-04-423095</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pollari M, Leivonen SK, Leppä S. Testicular diffuse large B-cell lymphoma-clinical, molecular, and immunological features. Cancers (Basel). 2021; 13(16): 4049. doi: 10.3390/cancers13164049</mixed-citation><mixed-citation xml:lang="en">Pollari M, Leivonen SK, Leppä S. Testicular diffuse large B-cell lymphoma-clinical, molecular, and immunological features. Cancers (Basel). 2021; 13(16): 4049. doi: 10.3390/cancers13164049</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ballen KK, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement. N Engl J Med. 2004; 350(20): 2081-2087. doi: 10.1056/NEJMcpc049003</mixed-citation><mixed-citation xml:lang="en">Ballen KK, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement. N Engl J Med. 2004; 350(20): 2081-2087. doi: 10.1056/NEJMcpc049003</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol. 2011; 29(20): 2766-2772. doi: 10.1200/JCO.2010.31.4187</mixed-citation><mixed-citation xml:lang="en">Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol. 2011; 29(20): 2766-2772. doi: 10.1200/JCO.2010.31.4187</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27(31): 5227-5232. doi: 10.1200/JCO.2009.22.5896</mixed-citation><mixed-citation xml:lang="en">Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27(31): 5227-5232. doi: 10.1200/JCO.2009.22.5896</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol. 2007; 18(1): 149-157. doi: 10.1093/annonc/mdl327</mixed-citation><mixed-citation xml:lang="en">Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol. 2007; 18(1): 149-157. doi: 10.1093/annonc/mdl327</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010; 21(5): 1046-1052. doi: 10.1093/annonc/mdp432</mixed-citation><mixed-citation xml:lang="en">Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010; 21(5): 1046-1052. doi: 10.1093/annonc/mdp432</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003; 21(1): 20-27. doi: 10.1200/JCO.2003.11.141</mixed-citation><mixed-citation xml:lang="en">Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003; 21(1): 20-27. doi: 10.1200/JCO.2003.11.141</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Gundrum JD, Mathiason MA, Moore DB, Ronald SG. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27: 5227-5232. doi: 10.1200/JCO.2009.22.5896</mixed-citation><mixed-citation xml:lang="en">Gundrum JD, Mathiason MA, Moore DB, Ronald SG. Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009; 27: 5227-5232. doi: 10.1200/JCO.2009.22.5896</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mazloom A, Fowler N, Medeiros LJ, Iyengoar P, Horace P, et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: The M.D. Anderson Cancer Center experience. Leuk Lymphoma. 2010; 51: 1217-1224. doi: 10.3109/10428191003793358</mixed-citation><mixed-citation xml:lang="en">Mazloom A, Fowler N, Medeiros LJ, Iyengoar P, Horace P, et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: The M.D. Anderson Cancer Center experience. Leuk Lymphoma. 2010; 51: 1217-1224. doi: 10.3109/10428191003793358</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann. Oncol. 2013; 24: 1385-1392. doi: 10.1093/annonc/mds621</mixed-citation><mixed-citation xml:lang="en">Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann. Oncol. 2013; 24: 1385-1392. doi: 10.1093/annonc/mds621</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A. The SCARE 2020 guideline: Updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg. 2020; 84: 226-230. doi: 10.1016/j.ijsu.2020.10.034</mixed-citation><mixed-citation xml:lang="en">Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A. The SCARE 2020 guideline: Updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg. 2020; 84: 226-230. doi: 10.1016/j.ijsu.2020.10.034</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
